Biotech Mid-Caps- Momentum Trade is Back ASCO Abstracts Provide Clinical Updates But as of 2 P EDT Stocks Are Being Hit By Profit Taking XBI at $92.39 Biotech mid-caps had a good week ending 5/18 as tracked by the top performing XBI which was up 2% and over 10% in 2018 YTD. The large cap […]
Update: 5/17…Mini-Rally Continues With Help From ASCO Abstracts XBI hits $93.78 above April highs, up 5.32% over 5 days, 10.5% YTD. IBB at April highs at $107.59, up 3.62% over 5 days, up 0.77% YTD Many Mid-Caps are hot: BLUE, CRSP, EXEL, FOLD, LGND, LOXO. See our list below. Gene editing stocks move up: CLLS, […]
Trump Speech on Plan for Lower Drug Prices 5/11 After close. Biotech and healthcare stocks were broadly higher. Key words by HHS Secretary were “complex” and “will take time”; more updates tomorrow. General objectives appear to be to lower list prices and squeeze middlemen like PBMs, offer Part-D type discount with Part-B drugs and promote […]
Update 5/8/18 Biotechs Rally Above Near Term Support (XBI) at SMA 20 XBI up 1.96% to $89.80. IBB up 1.35% to $103.79; twelve month quadruple bottom is near $100 level. Small and mid caps should outperform because of news and M&A potential. Large caps: Celgene (CELG) down 20.66% over 12 month lows at $82.80. Large caps: Abbvie(ABBV) […]
5/3 Testing February bottom and 200 MA of ~$100 on IBB and ~$85 on XBI. Red screen day. 2PM EDT Dow near flat line. Need to look for major gap up. Another potential negative on the horizon: “Bold Action on Drug Pricing” by Sect’y HHS. 5/2 Biotech Stocks Are About To Test 2018 Lows: It […]
Update 4/30… Vertex Pharmaceuticals (VRTX) Beat Consensus by 4% Financial Results: CF Revenues rose 33% Q’18 o Q’17 from $481M to $638M; GAAP net income down 15% ,$210M from $241M. Two Phase 3 triple combination clinical development programs are underway : VX-559 and VX-441 best for 2020 launch as well as pain and sickle cell R&D. […]
Update 4/25: Investors May See Value in Large Cap Biotech Amgen (AMGN) up 1.68%. Biogen (BIIB) holds Tuesday lows of $262 Up 2.78% today. IBB flat at $103.26 More earnings tomorrow but it is all about technicals holding the recent bottom. ========== Biotech Sector Watch on 2018 Earnings Interest Rates at 3% Rising Too Fast? […]
Speculative Biotech Stocks Sell-Off in Profit Taking: Gene Editing Biotech stocks held current levels but small caps and speculative stocks sold off with the XBI down 1%. Most large caps were in the green with an upgrade from Goldman Sachs helping Merck (MRK) up 2.4% with a bullish story on Keytruda. Amgen (AMGN) offers good […]
Updates: 4/19/18 GWPH hits $143 new high, then sold off holding $134 level, after big move from $105 on cannabis drug for severe epilepsy FDA Advisory go ahead. Biotechs broadly in the red except CRSP up 6.4% and NVCR up 5%. AstraZeneca (AZN) gained US approval for 1st line use of lung cancer drug. Novartis (NVS) shares […]
Updates 4/11/18 Biotechs Holding Above Recent Bottom 4/6/18 FBT up 2.8% over 5 days, up 6% YTD XBI up 1.77% over 5 days, up 2.19% YTD IBB down 0.72% over 5 days, down 3.67% YTD Busted Biotechs Review In our “Busted Biotechs” article we said that the XBI trade at 83-84 would be good, now […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.